Compare Adobe Systems Inc (ADBE) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Summit Therapeutics Inc — how do they compare? Adobe Systems Inc trades at $263.49 (market cap $104.82B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Adobe Systems Inc is far larger — about 8.7× Summit Therapeutics Inc's market cap, and Adobe Systems Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | SMMT | |
|---|---|---|
Market Cap | $104.82B | $12.06B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $26.98 |
52-Week Low | $193.41 | $12.55 |
Enterprise Value | $106.26B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $256.30, down 6.1% on the day amid broader tech sector weakness. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $5.96 versus $5.82 expected. Technical indicators show a bullish moving average trend but neutral oscillators, with key support at $252. Revenue grew to $23.77B in 2025 with impressive 28.69% net margins.
Adobe presents a compelling value opportunity trading below analyst consensus targets despite AI competition concerns. The company's robust cash flow generation and market leadership in creative software support long-term growth, though investor sentiment remains cautious due to CEO transition and AI disruption risks. Wall Street maintains a buy-heavy rating with $248.86 average price target.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
